Cargando…
Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein
BACKGROUND: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties. Th...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205289/ https://www.ncbi.nlm.nih.gov/pubmed/25323821 http://dx.doi.org/10.1186/s12977-014-0088-6 |
_version_ | 1782340674547351552 |
---|---|
author | Wan, Zhitao Chen, Xulin |
author_facet | Wan, Zhitao Chen, Xulin |
author_sort | Wan, Zhitao |
collection | PubMed |
description | BACKGROUND: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties. The antiviral activity of triptolide against human immunodeficiency virus type 1 (HIV-1) has not been reported. RESULTS: In this study, nanomolar concentrations of triptolide were shown to potently inhibit HIV-1 replication in vitro. To identify the step(s) of the HIV-1 replication cycle affected by triptolide, time-of-addition studies, PCR analysis and direct transfection of viral genomic DNA were performed. The results of these experiments indicated that triptolide acts at the stage of viral gene transcription. In addition, a luciferase-based reporter assay that allows quantitative analysis of long terminal repeat (LTR)-driven transcription showed that Tat-induced LTR activation was impaired in the presence of triptolide. Moreover, Western blot analysis of exogenous gene expression (driven by the human elongation factor 1 α subunit promoter) in transiently transfected cells revealed that triptolide specifically reduces the steady-state level of Tat protein, without suppressing global gene expression. Further studies showed that triptolide accelerates Tat protein degradation, which can be rescued by administration of the proteasome inhibitor MG132. Mutation analysis revealed that N-terminal domains of Tat protein and nuclear localization are required for triptolide to reduce steady-state level of Tat. CONCLUSION: This study suggests for the first time that triptolide exerts its anti-HIV-1 activity by specifically prompting the degradation of the virally encoded Tat protein, which is a novel mechanism of action for an anti-HIV-1 compound. This compound may serve as a starting point for developing a novel HIV-1 therapeutic approach or as a basic research tool for interrogating events during viral replication. |
format | Online Article Text |
id | pubmed-4205289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42052892014-10-23 Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein Wan, Zhitao Chen, Xulin Retrovirology Research BACKGROUND: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties. The antiviral activity of triptolide against human immunodeficiency virus type 1 (HIV-1) has not been reported. RESULTS: In this study, nanomolar concentrations of triptolide were shown to potently inhibit HIV-1 replication in vitro. To identify the step(s) of the HIV-1 replication cycle affected by triptolide, time-of-addition studies, PCR analysis and direct transfection of viral genomic DNA were performed. The results of these experiments indicated that triptolide acts at the stage of viral gene transcription. In addition, a luciferase-based reporter assay that allows quantitative analysis of long terminal repeat (LTR)-driven transcription showed that Tat-induced LTR activation was impaired in the presence of triptolide. Moreover, Western blot analysis of exogenous gene expression (driven by the human elongation factor 1 α subunit promoter) in transiently transfected cells revealed that triptolide specifically reduces the steady-state level of Tat protein, without suppressing global gene expression. Further studies showed that triptolide accelerates Tat protein degradation, which can be rescued by administration of the proteasome inhibitor MG132. Mutation analysis revealed that N-terminal domains of Tat protein and nuclear localization are required for triptolide to reduce steady-state level of Tat. CONCLUSION: This study suggests for the first time that triptolide exerts its anti-HIV-1 activity by specifically prompting the degradation of the virally encoded Tat protein, which is a novel mechanism of action for an anti-HIV-1 compound. This compound may serve as a starting point for developing a novel HIV-1 therapeutic approach or as a basic research tool for interrogating events during viral replication. BioMed Central 2014-10-17 /pmc/articles/PMC4205289/ /pubmed/25323821 http://dx.doi.org/10.1186/s12977-014-0088-6 Text en © Wan and Chen; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wan, Zhitao Chen, Xulin Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein |
title | Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein |
title_full | Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein |
title_fullStr | Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein |
title_full_unstemmed | Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein |
title_short | Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein |
title_sort | triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of tat protein |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205289/ https://www.ncbi.nlm.nih.gov/pubmed/25323821 http://dx.doi.org/10.1186/s12977-014-0088-6 |
work_keys_str_mv | AT wanzhitao triptolideinhibitshumanimmunodeficiencyvirustype1replicationbypromotingproteasomaldegradationoftatprotein AT chenxulin triptolideinhibitshumanimmunodeficiencyvirustype1replicationbypromotingproteasomaldegradationoftatprotein |